Teldra

Telmisartan

Essential HTN in adults. Reduction of CV morbidity in adults w/ manifest atherothrombotic CV disease (history of CHD, stroke, or peripheral arterial disease) or type 2 DM w/ documented target organ damage.

Essential HTN 40 mg once daily, can be increased to a max of 80 mg once daily if target BP is not achieved. CV prevention 80 mg once daily. Renal impairment Lower starting dose of 20 mg is recommended. Mild to moderate hepatic impairment Should not exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Severe hepatic impairment. Pregnancy (2nd & 3rd trimesters).

Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Not to be given to patients w/ cholestasis, biliary obstructive disorders or severe hepatic impairment. Symptomatic hypotension, especially after the 1st dose, may occur in patients who are vol &/or Na depleted by vigorous diuretic therapy, dietary salts restriction, diarrhoea, or vomiting. Dual blockade of the renin-angiotensin-aldosterone-system is not recommended. Patients whose vascular tone & renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (eg, patients w/ severe CHF or underlying renal disease, including renal artery stenosis). Not recommended for use in patients w/ primary aldosteronism. Patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Diabetic patients treated w/ insulin or antidiabetics. Hyperkalemia. MI or stroke in patients w/ ischaemic cardiopathy or ischaemic CV disease. Fructose intolerance. Black people. Periodic monitoring of K & creatinine serum levels in patients w/ impaired renal function. Combination w/ salt substitutes containing K, K-sparing diuretics, ACE inhibitors, AIIA, NSAIDS (including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), & trimethoprim. May affect ability to drive or operate machinery. Mild to moderate hepatic impairment. Not recommended during pregnancy (1st trimester) & lactation. Childn & adolescents <18 yr.

UTI including cystitis, URTI including pharyngitis & sinusitis; anaemia; hyperkalaemia; insomnia, depression; syncope; vertigo; bradycardia; hypotension, orthostatic hypotension; dyspnoea, cough; abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting, dry mouth, stomach discomfort; pruritus, hyperhidrosis, rash; back pain (eg, sciatica), muscle spasms, myalgia.

Increased risk of hyperkalemia w/ salt substitutes containing K, K-sparing diuretics, ACE inhibitors, AIIA, NSAIDs (including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), & trimethoprim. Increased serum K w/ K-sparing diuretics (eg, spironolactone, eplerenone, triamterene, or amiloride), K supplements, or K-containing salt substitutes. Reversible increases in serum lithium conc & toxicity. May reduce antihypertensive effect w/ NSAIDs (ie, ASA at anti-inflammatory dosage regimens, COX-2 inhibitors & non-selective NSAIDs). Vol depletion & risk of hypotension w/ high dose diuretics eg, furosemide (loop diuretic) & hydrochlorothiazide (thiazide diuretic). Increased BP lowering effect w/ other antihypertensive agents. May potentiate hypotensive effects w/ baclofen & amifostine. May aggravate orthostatic hypotension w/ alcohol, barbiturates, narcotics, or antidepressants. Reduced antihypertensive effect w/ corticosteroids (systemic route).

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx